证券代码：688351 证券简称：微电生理 公告编号：2025-017 上海微创电生理医疗科技股份有限公司 关于使用暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1 一、募集资金基本情况 经中国证券监督管理委员会《关于同意上海微创电生理医疗科技股份有限公 司首次公开发行股票注册的批复》（证监许可[2022]1587 号）核准，公司向社 会公开发行人民币普通股（A 股）7,060 万股，发行价格为 16.51 元/股，募集资 金总额为人民币 116,560.60 万元，扣除发行费用 9,572.61 万元后，实际募集资 金净额为 106,987.99 万元。上述募集资金实际到位时间为 2022 年 8 月 25 日， 已经大华会计师事务所（特殊普通合伙）审验，并出具了《上海微创电生理医疗 科技股份有限公司发行人民币普通股（A 股）7,060 万股后实收股本的验资报告》 （大华验字[2022]000559 号）。 基本情况 | 投资金额 | 65,000 万元（含本数） | | ...

证券代码：688351 证券简称：微电生理 公告编号：2025-016 上海微创电生理医疗科技股份有限公司 2025 年半年度募集资金存放与实际使用 情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意上海微创电生理医疗科技 股份有限公司首次公开发行股票注册的批复》（证监许可[2022]1587 号），公 司向社会公开发行人民币普通股（A 股）7,060 万股，发行价格为 16.51 元/股， 募集资金总额为人民币 116,560.60 万元，扣除发行费用 9,572.61 万元后，实际 募集资金净额为 106,987.99 万元。上述募集资金实际到位时间为 2022 年 8 月 25 日，已经大华会计师事务所（特殊普通合伙）审验，并出具了《上海微创电 生理医疗科技股份有限公司发行人民币普通股（A 股）7,060 万股后实收股本的 验资报告》（大华验字[2022]000559 号）。 二、募集资金管理情况 为规范募集资金的管理和使用，保护投资者权益 ...

上海微创电生理医疗科技股份有限公司的主营业务是电生理介入诊疗与消融治疗领域创新医疗器械研 发、生产和销售，致力于提供具备全球竞争力的"以精准介入导航为核心的诊断及消融治疗一体化解决 方案"。公司的主要产品是Columbus三维心脏电生理标测系统、EasyFinder3D磁定位型可调弯标测导 管、EasyLoop3D一次性使用磁定位环形标测导管、EasyLoop环肺静脉标测导管、EasyLoop一次性使用 心内标测电极导管、EasyFinder一次性使用可调弯标测导管、EasyFinder一次性使用固定弯标测导管、 EasyStars一次性使用星型磁电定位标测导管、FireMagicCool3D冷盐水灌注射频消融导管、FireMagic3D 磁定位型心脏射频消融导管、FireMagicPreciSense3D一次性使用磁定位微电极射频消融导管、 FireMagicTrueForce一次性使用压力监测磁定位射频消融导管等。公司冷冻消融设备、球囊型冷冻消融 导管、一次性使用压力监测磁定位射频消融导管凭借卓越性能与创新技术，获批纳入《2024年度上海市 生物医药"新优药械"产品目录》；同时，冷冻消融设备、球囊型冷冻消 ...

科创板融资余额较前一交易日增加4.98亿元，融券余额增加1482.57万元。322股融资余额环比增加，118 股融券余额环比增加。 | 688221 | 前沿 | 22759.43 | 15.18 | 0.00 | | -1.86 | | --- | --- | --- | --- | --- | --- | --- | | | 生物 | | | | | | | 688152 | 麒麟 | 15132.33 | 15.06 | 19.14 | 6.13 | 6.13 | | | 信安 | | | | | | | | 莱特 | | | | | | | 688150 | 光电 | 12192.81 | 14.42 | 1 11.34 | 13.71 | -2.77 | | | 晶丰 | | | | | | | 688368 | 明源 | 25218.58 | 14.05 | 19.82 | -5.05 | -5.05 | | 688029 | 南微 | 26888.1 1 | 13.59 | 153.44 | 1.36 | -1.95 | | | 医学 | | | | | | | | 燕麦 | | | | | | ...

Summary of Key Points from the Conference Call Industry Overview - The China SMID-cap medtech sector has seen a year-to-date increase of 47%, lagging behind the HKHSBIO Index which has gained over 100% [2][20] - The medtech space is characterized by innovation and globalization, similar to the biotech sector, indicating potential for further growth [2][5] Company Focus: MicroPort - MicroPort is identified as a prime beneficiary of positive trends in the medtech sector, with expectations to reach break-even by the second half of FY25 due to improved hospital procurement and cost control [2][20] - The strategic investment from Shanghai Industrial Investment Corp (SIIC) has reduced risk and is expected to enhance investor interest, contributing to a 60% rally in MicroPort's share price since the investment [20][24] - Sales forecasts for MicroPort have been raised by 1-3% for 2025-2027, with a price target increase from HK$8.60 to HK$17.20, extending the timeframe to June 2026 [20][25] Financial Performance and Projections - MicroPort's revenue is projected to grow from HK$1,031 million in FY24 to HK$1,602 million by FY27, reflecting a compound annual growth rate (CAGR) of approximately 20% [37] - The company aims to reduce its operating expenses/sales ratio from 96% in 2023 to below 50% by 2026, which is expected to improve profitability [24][29] - Adjusted net income is anticipated to turn positive by FY26, with a projected net margin of 5.1% by FY27 [37] Market Dynamics - Recent policy changes favor innovation in the medtech sector, with a significant increase in approvals for innovative medical devices by the NMPA, up 87% year-over-year in 1H25 [5][20] - The globalization of China's medtech sector is accelerating, with overseas sales of top Chinese medtech companies expected to grow significantly [5][20] Risks and Considerations - Key risks include potential earnings volatility, higher-than-expected financial obligations, and geopolitical risks that could impact the medtech sector [35][36] - Price cut risks remain a concern, particularly for products subject to volume-based procurement (VBP) [42] Conclusion - The outlook for the China SMID-cap medtech sector, particularly for MicroPort, remains positive, driven by strategic investments, favorable policy changes, and anticipated improvements in financial performance [2][20][24]

Group 1 - The core viewpoint of the news is that Shanghai MicroPort CardioFlow Medtech Corp. (微电生理) has shown significant financial growth in its latest quarterly report, with a notable increase in revenue and net profit [1] - As of August 19, 2025, the company's stock price closed at 26.68 yuan, reflecting a 3.81% increase, with a trading volume of 12.54 million shares and a transaction amount of 328 million yuan [1] - The company reported total revenue of 104 million yuan for the first quarter of 2025, representing a year-on-year growth of 16.77%, and a net profit attributable to shareholders of 17.87 million yuan, which is a 328.63% increase year-on-year [1] Group 2 - The company has a strong liquidity position, with a current ratio of 12.972 and a quick ratio of 11.841, indicating robust financial health [1] - The company has a low debt level, with an asset-liability ratio of 8.11%, suggesting minimal financial risk [1] - Shanghai MicroPort CardioFlow Medtech Corp. was established in 2010 and is primarily engaged in the manufacturing of specialized medical equipment, with a registered capital of 47.06 million yuan [1] Group 3 - The company has made investments in 7 enterprises and has participated in 197 bidding projects, indicating active engagement in business development [2] - The company holds 38 trademark registrations and 324 patents, showcasing its commitment to innovation and intellectual property [2] - Additionally, the company possesses 98 administrative licenses, reflecting its compliance and operational capabilities [2]

从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均59.49倍，行业中值40.19倍，微电生理排 名第111位。 8月19日，微电生理今日收盘26.68元，上涨3.81%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到190.90倍，创316天以来新低，总市值125.56亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入1.04亿元，同比16.77%；净利润1787.05万元， 同比328.63%，销售毛利率60.56%。 截至2025年一季报，共有7家机构持仓微电生理，其中基金7家，合计持股数166.93万股，持股市值0.33 亿元。 上海微创电生理医疗科技股份有限公司的主营业务是电生理介入诊疗与消融治疗领域创新医疗器械研 发、生产和销售，致力于提供具备全球竞争力的"以精准介入导航为核心的诊断及消融治疗一体化解决 方案"。公司的主要产品是Columbus三维心脏电生理标测系统、EasyFinder3D磁定位型可调弯标测导 管、EasyLoop3D一次性使用磁定位环形标测导管、EasyLoop环肺静脉标测导管、EasyLoop一次性使用 心内标测电极导管、EasyFinder一次性 ...

8月14日，微电生理今日收盘22.83元，下跌3.91%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到163.35倍，总市值107.44亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.76倍，行业中值39.14倍，微电生理排 名第111位。 最新一期业绩显示，2025年一季报，公司实现营业收入1.04亿元，同比16.77%；净利润1787.05万元， 同比328.63%，销售毛利率60.56%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13微电生理163.35206.336.10107.44亿行业平均 55.7651.784.91117.92亿行业中值39.1439.592.8556.79亿1九安医疗11.1811.310.88188.72亿2英科医疗 14.7815.931.32233.49亿3山东药玻16.1716.211.86152.90亿4新华医疗16.3115.111.33104.53亿5振德医疗 17.0416.061.0861.87亿6奥美医疗17.0716.731.7561.68亿7九强生物17.6516.412.1687.42亿8康德莱 18 ...

来源：金融界 主力资金净流出居前的分别为安必平（1174.99万元）、东富龙（1070.65万元）、安杰思（995.13万 元）、微电生理（983.9万元）、可孚医疗（916.41万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1300760迈瑞医疗230.71-0.031.07亿元7.18%2300003 乐普医疗17.276.931.07亿元5.73%3301363美好医疗20.037.175599.57万元11.04%4603987康德莱 9.235.734851.48万元12.43%5870199倍益康42.581.383949.32万元7.52%6002551尚荣医疗4.649.953736.73 万元22.93%7688068热景生物243.022.543614.97万元6.9%8688314康拓医疗40.08.113278.73万元 15.1%9688108赛诺医疗20.4420.022762.62万元19.98%10832278鹿得医疗12.484.962727.93万元13.05% 8月8日，医疗器械行业上涨0.93%，今日主力资金流出6.11亿元，成分股59只上涨，39只下跌。 ...

Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary of company secretaries in the medical consumables sector is 817,000 yuan [2] - Salary distribution among company secretaries is as follows: below 500,000 yuan (30%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (27%), and above 2,000,000 yuan (2%) [2] - The top three highest-paid company secretaries are: Gong Xingliang from Nanwei Medical (2.2161 million yuan), Zhu Yu from Microelectrophysiology (1.6764 million yuan), and Lin Qing from Weigao Orthopedics (1.6142 million yuan) [2] Age and Education Distribution - The age distribution of company secretaries shows that those aged 40-50 constitute 45%, while those over 50 account for 14%, and those aged 30-40 make up 36% [1] - The educational background of company secretaries is as follows: 7% have an associate degree, 45% hold a bachelor's degree, 43% have a master's degree, and 5% possess a doctoral degree [1] Salary Changes - Among company secretaries with over two years of tenure, the largest salary decrease was observed for Bai Xue from Xishan Technology, with a year-on-year decline of 54.09% [2] - The highest salary increase was recorded for Chen Bin from Weili Medical, with a year-on-year increase of 191.72% [2]